| 治疗心房纤颤和扑动的新药决奈达隆 |
| 投稿时间：2010-03-04 修订日期：2010-03-11 点此下载全文 |
| 引用本文：吕娟丽,刘洋,李彦,刘振华.治疗心房纤颤和扑动的新药决奈达隆[J].药学实践杂志,2011,29(1):41~44 |
| 摘要点击次数: 929 |
| 全文下载次数: 110 |
|
|
| 中文摘要:决奈达隆为胺碘酮的类似物,结构中不含碘,减少了碘所致的器官毒性,为新型的抗心律失常药。2009年7月1日获FDA批准,用于治疗心房纤颤或心房扑动的心脏病患者。本文通过对决奈达隆进行文献检索,对其药理作用、药动学、临床评价、药物相互作用、不良反应等方面进行了综述。 |
| 中文关键词:决奈达隆 心房纤颤 心房扑动 抗心律失常药 |
| |
| Dronedarone a new drug for atrial fibrillation or atrial flutter |
|
|
| Abstract:Dronedarone is analogues as amiodarone, the structure is not iodine, reducing iodine-induced organ toxicity, is one of the new anti-arrhythmia drugs. on July 1, 2009 , It has been approved by FDA for the treatment of atrial fibrillation or atrial flutter in patients with heart disease. In this paper, after a literature search for Dronedarone with key words, the pharmacological , pharmacokinetics, clinical evaluation, drug interactions and adverse reactions of dronedarone are reviewed. |
| keywords:dronedarone atrial fibrillation atrial flutter anti-arrhythmia drugs |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
